sorafenib has been researched along with tyrosine in 6 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (tyrosine) | Trials (tyrosine) | Recent Studies (post-2010) (tyrosine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 44,273 | 846 | 8,225 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Blechacz, BR; Bronk, SF; Gores, GJ; Sirica, AE; Smoot, RL; Werneburg, NW | 1 |
| Choe, SW; Kim, MJ; Kim, YH; Lee, YJ; P Oh, S; Sprecher, D | 1 |
| Al-Salama, ZT; Scott, LJ; Syed, YY | 1 |
| Christen, KE; Davis, RA; Kennedy, D | 1 |
| Abu-Gharbieh, E; Abushawish, KYI; Al-Hroub, HM; Alzoubi, KH; Bustanji, Y; El-Huneidi, W; Elgendy, SM; Giddey, AD; Mousa, M; Omar, HA; Semreen, MH; Soares, NC; Soliman, SSM | 1 |
| Duda, DG; Jain, RK | 1 |
1 review(s) available for sorafenib and tyrosine
| Article | Year |
|---|---|
Lenvatinib: A Review in Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Treatment Outcome; Tyrosine | 2019 |
5 other study(ies) available for sorafenib and tyrosine
| Article | Year |
|---|---|
Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
Topics: Animals; Apoptosis; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Enzyme Activation; Humans; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyridines; Rats; Rats, Inbred F344; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Tyrosine | 2009 |
Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia.
Topics: Activin Receptors, Type I; Activin Receptors, Type II; Administration, Oral; Administration, Topical; Anemia; Angiogenesis Inhibitors; Animals; Arteriovenous Malformations; Disease Models, Animal; Erlotinib Hydrochloride; Gastrointestinal Hemorrhage; Hemoglobins; Image Processing, Computer-Assisted; Indazoles; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Skin; Sorafenib; Sulfonamides; Sulfones; Telangiectasia, Hereditary Hemorrhagic; Tyrosine; Vascular Endothelial Growth Factor A; Wound Healing | 2017 |
Psammaplysin F increases the efficacy of bortezomib and sorafenib through regulation of stress granule formation.
Topics: Animals; Bortezomib; Chlorocebus aethiops; Cytoplasmic Granules; Drug Resistance, Neoplasm; HEK293 Cells; HeLa Cells; Humans; MCF-7 Cells; Neoplasms; Sorafenib; Spiro Compounds; Tyrosine; Vero Cells | 2019 |
Multi-Omics Analysis Revealed a Significant Alteration of Critical Metabolic Pathways Due to Sorafenib-Resistance in Hep3B Cell Lines.
Topics: Alanine; Amino Acids; Antineoplastic Agents; Biomarkers; Calpain; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Folic Acid Antagonists; Glucose; Humans; L-Iditol 2-Dehydrogenase; Liver Neoplasms; Metabolic Networks and Pathways; Nucleotides; Phosphatidylcholines; Proline; Protein Kinase Inhibitors; Proteome; Proteomics; Sorafenib; Succinic Acid; Superoxide Dismutase; Tyrosine; Ubiquitin Thiolesterase; Uridine Diphosphate | 2022 |
Revisiting Antiangiogenic Multikinase Inhibitors in the Era of Immune Checkpoint Blockade: The Case of Sorafenib.
Topics: Angiogenesis Inhibitors; Endothelial Cells; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Liver Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Receptor Protein-Tyrosine Kinases; Sorafenib; Tyrosine | 2022 |